Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the company announced its experimental pain drug, VX-993, failed a key mid-stage clinical trial ...

Anthropic launched Claude Opus 4.1 today, an upgraded version of its flagship AI model that achieves 74.5% accuracy on ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Anthropic has released Claude Opus 4.1, which is said to deliver better coding and agent performance with improved safety.

Vertex Pharmaceuticals (VRTX) stock is sliding after the company said it won't advance its pain treatment into the next phase ...

Anthropic Claude 4.1 was released today is an upgrade to Anthropic's Claude Opus 4 model with key improvements. This was ...

Anthropic says Claude Opus 4.1 improves software engineering accuracy to 74.5%. That compares to 62.3% with Claude Sonnet 3.7 and 72.5% with Claude Opus 4. More specifically, the updated model is ...

Palantir rose after earnings blew past Wall Street estimates. Shares of Vertex Pharmaceuticals and Hims & Hers plummeted on ...

Anthropic has launched Claude Opus 4.1, an incremental update to its flagship AI model, offering slight performance boosts in ...

A Massachusetts biotech working on a class of medicines called circular RNA therapeutics beat out companies from around the ...